$EVAX

Evaxion A/S (NASDAQ: EVAX) will present new data on EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting. The data validate EVX-04's potential, showing broad patient coverage and immune response induction in preclinical models. EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens, selected using Evaxion's AI-Immunology platform.

Evaxion (NASDAQ: EVAX) will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The trial, involving advanced melanoma patients, showed a 75% objective response rate. EVX-01 is designed with Evaxion's AI-Immunology platform and is being evaluated as a treatment for advanced melanoma.

Evaxion A/S (NASDAQ: EVAX), a Danish biotech company, won the 2026 International Prix Galien Award for its AI-Immunology™ platform, the first time a Danish company has received the honor. The award recognizes the platform as the best digital health solution. Evaxion's CEO and founder accepted the award in New York. The company's AI platform is used to develop immunotherapies for cancer, infectious, and autoimmune diseases.

Biotech stocks rallied on Monday, with Silence Therapeutics (SLN) up 125% after a $1.3B acquisition by Merck, SCWorx (WORX) up 105% on a new healthcare deal, and Disc Medicine (IRON) up 41% on positive trial results. Actinium (ATNM) and Evaxion (EVAX) also saw gains on clinical updates.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All patients showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 showed a 75% objective response rate, with 25% of patients achieving complete response.

Evaxion A/S (EVAX), a clinical-stage TechBio company, is nearing a key milestone with its AI-designed personalized cancer vaccine, EVX-01. The vaccine is being evaluated in a Phase 2 trial in combination with Merck's (MRK) KEYTRUDA for advanced melanoma patients. Each patient receives a unique vaccine based on their individual biology.

Evaxion A/S (NASDAQ: EVAX) will present new immune data for its personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The data comes from a phase 2 trial of EVX-01 combined with pembrolizumab in advanced melanoma patients, showing a 75% objective response rate. Full three-year data will be presented at ESMO 2026, including insights on the vaccine's effects as a standalone therapy.

Evaxion Biotech (EVAX) has expanded its AI-Immunology platform to target autoimmune diseases, adding to its focus on cancer and infectious diseases. The company is testing a tolerogenic vaccine and an autoantibody binder, with initial data to be presented at a summit in November 2026. Evaxion believes its platform could offer more effective and safer treatments than current options, potentially opening new partnerships and commercial opportunities.

Evaxion A/S reported Q2 2026 revenue of $0 and a net loss of $3.7 million, improving from a $4.8 million loss in Q2 2025. Shares rose 5.4% to $3.32 as investors focused on pipeline progress and cash runway through H2 2027. The company's AI-Immunology™ platform is advancing vaccine candidates for cancer and infectious diseases.

Analysts maintained Buy ratings on Evaxion Biotech (EVAX) and Boston Scientific (BSX). Thomas Flaten set a $9.00 target for EVAX, while Matthew Taylor set a $60.00 target for BSX. Both stocks have consensus Buy ratings with significant upside potential according to TipRanks.